Skip Navigation

Materials Distribution Policy

Materials Distribution Policy

Publication in Molecular Plant requires that authors make available all novel materials integral to the reported results for non-commercial research purposes. A statement concerning the availability, or restrictions on availability, should be included in the Methods section of the paper; it will be up to referees to decide if any such restrictions are reasonable

Such materials include mutants, genetic stocks, transgenic plants, cell lines, recombinant constructs, vectors, viruses, enzymes, antibodies, and software. In general, authors are expected to deposit novel materials in public repositories, to the extent possible and consistent with the policy stated here. All manuscripts submitted to Molecular Plant will be reviewed for compliance with journal policy and should include the following statement as an unnumbered footnote: "The author(s) responsible for distribution of materials integral to the findings presented in this article in accordance with the policy described in the Instructions for Authors ( is (are): John D. Author (" Contact information for the author(s) responsible for distribution of materials must be provided.

Authors should expect to comply with requests for materials within 60 days. Requestors should expect to comply with conditions (including via a signed Materials Transfer Agreement) that do not unreasonably limit use for non-commercial research purposes. Authors are expected to make materials available to all qualified investigators in private or public organizations on similar, if not identical, terms. If authors do not possess rights to distribute materials, upon request they should supply contact information for the source of the materials. and should make their best efforts to facilitate the transfer of these materials within the expected timeframe, preferably by arranging for standard, reasonable terms in advance of publication or even prior to the initiation of research with such materials. In the case of unreasonable delay (and lack of extenuating circumstances, such as travel or illness, or special circumstances, such as significant and reasonable regulatory or safety issues), the requestor may contact the managing editor. Non-compliance with this policy by authors may result in denial of future rights to publish in Molecular Plant and/or notification of authors' funding agencies or employers and/or retraction of the publication describing the materials on the grounds that it is not possible to confirm the results and conclusions. It is reasonable for authors to require that requestors obtain a license for research use of patented materials.

Reasonable approaches to protect ownership rights are allowable if they are described in the Methods. For instance, mutants or alleles that exist only in proprietary inbred lines may be provided via hybrids if the inbred line itself is not integral to the findings. In lieu of providing plasmid constructs, complete DNA sequences necessary to replicate them could be provided via a public repository or supplementary data, assuming component elements are readily available and the construct is not so complex that it could not be replicated in a timely manner. Authors may reasonably limit amounts of materials (such as enzymes, antibodies, and natural products) that will be distributed in the case that substantial effort is required for their isolation. Sufficiently detailed procedures must be provided to permit production of such materials; detailed protocols should be provided as Supplementary Data in Molecular Plant.